SinoCelltech Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.

Phase 1

Not yet recruiting

Conditions: TED

Interventions: Drug: SCTT11
Drug: Placebo

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 100

Registration Number: NCT06769984

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

Phase 1

Not yet recruiting

Conditions: Respiratory Syncytial Virus

Interventions: Biological: SCTV02
Biological: Placebo

First Posted Date: 2025-01-01

Last Posted Date: 2025-01-03

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 480

Registration Number: NCT06754605

Locations: 🇨🇳
Hebei Zhongshiyou Central Hospital, Langfang, Hebei, China
🇨🇳
Luzhou Center for Disease Control and Prevention, Luzhou, Sichuan, China

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients with NAMD (phase I Portion)

Phase 1

Not yet recruiting

Conditions: NAMD

Interventions: Drug: SCT520FF

First Posted Date: 2024-11-04

Last Posted Date: 2024-11-04

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 15

Registration Number: NCT06672536

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients With Advanced Malignant Solid Tumours.

Phase 1

Not yet recruiting

Conditions: Advanced Malignant Solid Tumours

Interventions: Drug: SCTB41

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 441

Registration Number: NCT06600022

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

Not yet recruiting

Conditions: Non-Hodgkin Lymphoma, B-cell

Interventions: Drug: SCTB35 injection

First Posted Date: 2024-03-19

Last Posted Date: 2024-03-22

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 76

Registration Number: NCT06318884

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.

Phase 1

Not yet recruiting

Conditions: Advanced Malignant Solid Tumours

Interventions: Drug: SCTB14

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-15

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 515

Registration Number: NCT06304818

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Phase 1

Recruiting

Conditions: Relapsed or Refractory Hematologic Malignancies

Interventions: Biological: SCTC21C

First Posted Date: 2024-02-09

Last Posted Date: 2024-04-22

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 74

Registration Number: NCT06252298

Locations: 🇨🇳
Beijing Chaoyang Hospital ,Capital Medical University, Beijing, Beijing, China

Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis

Phase 2

Not yet recruiting

Conditions: Axial Spondyloarthritis

Interventions: Drug: SCT650C

First Posted Date: 2024-01-09

Last Posted Date: 2024-01-09

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 168

Registration Number: NCT06197009

Locations: 🇹🇷
Hacettepe University Faculty of Medicine, Ankara, Hacettepe Mh., Turkey

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Phase 3

Active, not recruiting

Conditions: HPV InfectioN
HPV-Related Carcinoma

Interventions: Biological: placebo
Biological: Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）

First Posted Date: 2023-09-18

Last Posted Date: 2023-09-18

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 18000

Registration Number: NCT06041061

Locations: 🇨🇳
Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China
🇨🇳
Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China
🇨🇳
Shanxi Center for Disease Control and Prevention, Taiyuan, Shanxi, China

and more 2 locations

A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines

Phase 2

Not yet recruiting

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Biological: SCTV01E-2
Biological: SCTV01E

First Posted Date: 2023-07-06

Last Posted Date: 2023-07-06

Lead Sponsor: Sinocelltech Ltd.

Target Recruit Count: 600

Registration Number: NCT05933512

Home Terms & Conditions Privacy Policy